{"entity":{"id":"nct04722978","kind":"trial","name":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","aka":[],"tldr":"A phase 3 trial of gemcitabine and carboplatin in triple-negative breast cancer, run by Sun Yat-Sen University Cancer Center, now recruiting.","summary":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer is a phase 3, randomised interventional study registered as NCT04722978 by Sun Yat-Sen University Cancer Center, with a registry enrolment figure of 228 participants, started 2021-04-20 and due to reach its primary completion in 2026-06. Interventions recorded: Gemcitabine and carboplatin plus antibiotic (moxifloxacin); Gemcitabine combined with carboplatin plus placebo. Conditions listed: Triple Negative Breast Cancer. Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04722978","url":"https://clinicaltrials.gov/study/NCT04722978"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["gemcitabine","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04722978","phase":"3","setting":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer : a Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial","sponsor":"Sun Yat-Sen University Cancer Center","participation":[{"nct":"NCT04722978","source":"https://clinicaltrials.gov/study/NCT04722978","fetchedAt":"2026-10-07T16:53:25.962Z","studySha256":"7a3437965c5ed7cc7dc3b8e579a67fd1ff1db2597be271646c5f5069d82528a6","overallStatus":"RECRUITING","lastUpdatePosted":"2025-12-17","leadSponsor":"Sun Yat-Sen University Cancer Center","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":228,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2021-04-20","startedType":"actual","enrolled":228,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04722978/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}